Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Reinhard, Henrik ^a   Garde, Ellen ^b   Skimminge, Arnold ^b   Åkeson, Per ^b   Ramsøy, Thomas Z ^b,f   Winther, Kaj ^c   Parving, Hans Henrik ^b,d   Rossing, Peter ^a   Jacobsen, Peter K ^a,e  

^a STENO DIABETES CENTER   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Department of International Economics and Management   (Denmark)

Author keywords

3 D magnetic resonance imaging; Brain parenchymal fraction; Plasma NT proBNP; Type 2 diabetes; White matter hyperintensities

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; WHITE MATTER;

ADULT; AGED; ATROPHY; BIOLOGICAL MARKERS; BRAIN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LEUKOENCEPHALOPATHIES; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; ORGAN SIZE; PEPTIDE FRAGMENTS; RISK ASSESSMENT; RISK FACTORS; UP-REGULATION;

EID: 84866871895     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-119     Document Type: Article

References (42)

1. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286(4):421-426. 10.1001/jama.286.4.421, 11466120.
2. Gaede P, Lund-Andersen H, Parving H-H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358(6):580-591. 10.1056/NEJMoa0706245, 18256393.
3. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350(7):655-663. 10.1056/NEJMoa031994, 14960742.
4. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. Br Med J 2010, 341:c3666.
5. Tarnow L, Gall M-A, Hansen BV, et al. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006, 49:2256-2262. 10.1007/s00125-006-0359-4, 16937127.
6. Whiteley W, Wardlaw J, Dennis M, et al. Blood biomarkers for the diagnosis of acute cerebrovascular diseases: a prospective cohort study. Cerebrovasc Dis 2011, 32(2):141-147. 10.1159/000328517, 21778711.
7. Shibazaki K, Kimura K, Iguchi Y, et al. Plasma brain natriuretic peptide can be a biological marker to distinguish cardioembolic stroke from other stroke types in acute ischemic stroke. Intern Med 2009, 48(5):259-264. 10.2169/internalmedicine.48.1475, 19252345.
8. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997, 28(3):652-659. 10.1161/01.STR.28.3.652, 9056627.
9. Hachinski V. World Stroke Day 2008: "little strokes, big trouble". Stroke 2008, 39(9):2407-2420. 10.1161/STROKEAHA.108.531681, 18723419.
10. Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis 2003, 16(3):280-285. 10.1159/000071128, 12865617.
11. Reinhard H, Hansen PR, Persson F, et al. Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant 2011, 26(10):3242-3249. 10.1093/ndt/gfr009, 21372253.
12. Reinhard H, Wiinberg N, Hansen PR, et al. NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis. Cardiovasc Diabetol 2011, 10:71. 10.1186/1475-2840-10-71, 3164620, 21812947.
13. Reinhard H, Hansen PR, Wiinberg N, et al. NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients. Cardiovasc Diabetol 2012, 11:19. 10.1186/1475-2840-11-19, 3310741, 22390472.
14. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992, 40(9):922-935.
15. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002, 17(1):479-489. 10.1006/nimg.2002.1040, 12482100.
16. Pikula A, Beiser AS, DeCarli C, et al. Multiple biomarkers and risk of clinical and subclinical vascular brain injury: the Framingham Offspring Study. Circulation 2012, 125(17):2100-2107. 10.1161/CIRCULATIONAHA.110.989145, 22456473.
17. Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010, 41(4):600-606. 10.1161/STROKEAHA.109.570044, 2847685, 20167919.
18. Wada A, Tsutamoto T, Matsuda Y, et al. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 1994, 89(5):2232-2240. 10.1161/01.CIR.89.5.2232, 7910118.
19. Schultz HD, Gardner DG, Deschepper CF, et al. Vagal C-fiber blockade abolishes sympathetic inhibition by atrial natriuretic factor. Am J Physiol 1988, 255(1 Pt 2):R6-R13.
20. Takahashi K, Totsune K, Sone M, et al. Human brain natriuretic peptide-like immunoreactivity in human brain. Peptides 1992, 13(1):121-123. 10.1016/0196-9781(92)90149-W, 1535705.
21. Brosnan MJ, Clark JS, Jeffs B, et al. Genes encoding atrial and brain natriuretic peptides as candidates for sensitivity to brain ischemia in stroke-prone hypertensive rats. Hypertension 1999, 33(1 Pt 2):290-297.
22. Jiang C, Lu H, Vincent KA, et al. Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1 alpha. Physiol Genomics 2002, 8(1):23-32.
23. Nakagawa K, Yamaguchi T, Seida M, et al. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc Dis 2005, 19(3):157-164. 10.1159/000083249, 15644628.
24. Sharma JC, Ananda K, Ross I, et al. N-terminal proBrain natriuretic peptide levels predict short-term poststroke survival. J Stroke Cerebrovasc Dis 2006, 15(3):121-127. 10.1016/j.jstrokecerebrovasdis.2006.03.003, 17904063.
25. Iltumur K, Yavavli A, Apak I, et al. Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke. Am Heart J 2006, 151(5):1115-1122. 10.1016/j.ahj.2005.05.022, 16644347.
26. Modrego PJ, Boned B, Berlanga JJ, et al. Plasmatic B-type natriuretic peptide and C-reactive protein in hyperacute stroke as markers of CT-evidence of brain edema. Int J Med Sci 2008, 5(1):18-23. 2204043, 18219371.
27. Peng XL, Lin ZP, Zhang RK, et al. [B-type natriuretic peptides and subclinical target organ damage in essential hypertensive patients]. Nan Fang Yi Ke Da Xue Xue Bao 2010, 30(10):2347-2350.
28. Abdullah SM, Khera A, Das SR, et al. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). Am J Cardiol 2005, 96(9):1284-1289. 10.1016/j.amjcard.2005.06.073, 16253599.
29. Wiersma JJ, van der Zee PM, van Straalen JP, Fischer JC, van Eck-Smit BL, Tijssen JG, Trip MD, Piek JJ, Verberne HJ. NT-pro-BNP is associated with inducible myocardial ischemia in mildly symptomatic type 2 diabetic patients. Int J Cardiol 2010, 145(2):295-6. November 19, 10.1016/j.ijcard.2009.10.035, 19900726.
30. Sakai H, Tsutamoto T, Ishikawa C, et al. Direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP secretion and extent of coronary artery stenosis in patients with stable coronary artery disease. Circ J 2007, 71(4):499-505. 10.1253/circj.71.499, 17384449.
31. Magnusson M, Jovinge S, Shahgaldi K, et al. Brain natriuretic peptide is related to diastolic dysfunction whereas urinary albumin excretion rate is related to left ventricular mass in asymptomatic type 2 diabetes patients. Cardiovasc Diabetol 2010, 9:2. 10.1186/1475-2840-9-2, 2817679, 20078898.
32. Christensen LL, Anker-Nielsen A, Almdal TP. Development in Quality of Treatment in Complicated Type 2 Diabetes Assessed by the Proportion of Patients Reaching ADA Goals. Diab 2010, 59:A180-A181.
33. Gaede P, Hildebrandt P, Hess G, et al. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005, 48(1):156-163. 10.1007/s00125-004-1607-0, 15619076.
34. Nakatsuji H, Kishida K, Funahashi T, et al. Hyperinsulinemia correlates with low levels of plasma B-type natriuretic peptide in Japanese men irrespective of fat distribution. Cardiovasc Diabetol 2012, 11:22. 10.1186/1475-2840-11-22, 3320543, 22397400.
35. Magnusson M, Melander O, Israelsson B, et al. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004, 27(8):1929-1935. 10.2337/diacare.27.8.1929, 15277419.
36. Cakir Z, Saritas A, Emet M, et al. A prospective study of brain natriuretic peptide levels in three subgroups: Stroke with hypertension, stroke without hypertension, and hypertension alone. Ann Indian Acad Neurol 2010, 13(1):47-51. 10.4103/0972-2327.61277, 2859588, 20436747.
37. Saritas A, Cakir Z, Emet M, et al. Factors affecting the B-type natriuretic peptide levels in stroke patients. Ann Acad Med Singapore 2010, 39(5):385-389.
38. Fukuda H, Kitani M. Differences between treated and untreated hypertensive subjects in the extent of periventricular hyperintensities observed on brain MRI. Stroke 1995, 26(9):1593-1597. 10.1161/01.STR.26.9.1593, 7660404.
39. Mantyla R, Erkinjuntti T, Salonen O, et al. Variable agreement between visual rating scales for white matter hyperintensities on MRI. Comparison of 13 rating scales in a poststroke cohort. Stroke 1997, 28(8):1614-1623. 10.1161/01.STR.28.8.1614, 9259759.
40. van HB, de Leeuw FE, Weinstein HC, et al. Brain imaging in patients with diabetes: a systematic review. Diabetes Care 2006, 29(11):2539-2548. 10.2337/dc06-1637, 17065699.
41. Jongen C, van der Grond J, Kappelle LJ, et al. Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus. Diabetologia 2007, 50(7):1509-1516. 10.1007/s00125-007-0688-y, 1914300, 17492428.
42. De BJ, Tiehuis AM, van den Berg E, et al. Progression of cerebral atrophy and white matter hyperintensities in patients with type 2 diabetes. Diabetes Care 2010, 33(6):1309-1314. 10.2337/dc09-1923, 2875445, 20299484.